<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146116</url>
  </required_header>
  <id_info>
    <org_study_id>201812801</org_study_id>
    <nct_id>NCT04146116</nct_id>
  </id_info>
  <brief_title>Nasal Decolonization for Orthopedic Trauma Patients</brief_title>
  <official_title>Feasibility of Pre-operative Povidone Iodine Decolonization Among Orthopedic Trauma Surgery Patients To Reduce Staphylococcus Aureus Surgical Site Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Professional Disposables International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many surgical site infections are caused by bacteria that is transferred from a patient's&#xD;
      nose to their open surgical wound. Some small studies have shown that putting povidone-iodine&#xD;
      in a patient's nose reduces this risk. This study aims to evaluate the real-world&#xD;
      effectiveness of nasal povidone-iodine (PROFEND®) in a group of 50 patients at the University&#xD;
      of Iowa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1. Evaluate the real-world effectiveness of intranasal povidone-iodine (PROFEND®) in&#xD;
      reducing Staphylococcus aureus colonization and surgical site infections (SSIs).&#xD;
&#xD;
      Aim 1a. Evaluate patients after surgery to determine S. aureus colonization and to survey&#xD;
      patients on tolerability of intranasal povidone-iodine decolonization. The intranasal&#xD;
      povidone-iodine swab will be administered to the patient's nares around one hour prior to the&#xD;
      first surgical incision. It will then be re-applied around 12 hours later, for a total of two&#xD;
      applications within a 24 hour period.&#xD;
&#xD;
      During the same visit at 24 hours after surgery, patients will also be administered a&#xD;
      questionnaire to determine the tolerability of intranasal povidone-iodine decolonization.&#xD;
      Questions will be asked about adverse events (e.g., itching, irritation) and how intranasal&#xD;
      povidone-iodine felt (very pleasant, pleasant, neutral, unpleasant, very unpleasant).&#xD;
&#xD;
      Based on the data obtained from this aim, we will summarize the patient acceptance of&#xD;
      intranasal povidone-iodine.&#xD;
&#xD;
      Aim 1b. Compare the rates of SSI among orthopaedic trauma surgery patients who received&#xD;
      intranasal povidone-iodine to similar patients who received orthopedic trauma surgery before&#xD;
      intranasal povidone-iodine implementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Actual">June 8, 2021</completion_date>
  <primary_completion_date type="Actual">June 8, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>50 patients will receive PROFEND intranasal povidone-iodine prior to surgery and after surgery. The study aims to evaluate the real-world effectiveness of PROFEND® in reducing S. aureus colonization and surgical site infections (SSIs).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Staphylococcus aureus nasal colonization</measure>
    <time_frame>Within 6 hours after first dose of povidone-iodine</time_frame>
    <description>A dry, sterile, rayon swab will be used to sample the anterior apex portion of the right and left nostril. This swab will be tested for S. aureus bacteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Staphylococcus aureus nasal colonization</measure>
    <time_frame>Within 24 hours after surgery</time_frame>
    <description>A dry, sterile, rayon swab will be used to sample the anterior apex portion of the right and left nostril. This swab will be tested for S. aureus bacteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical site infection</measure>
    <time_frame>Within 30 days of surgery</time_frame>
    <description>Surgical site infection as defined by the Centers for Disease Control and Prevention National Healthcare Safety Network.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Nasal povidone-iodine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal povidone-iodine (PDI PROFEND) will be applied to the patients' noses before orthopedic trauma surgery and after surgery. This intranasal povidone-iodine was developed under the Tentative Final Monograph for Health-Care Antiseptic Drug Products 21 CFR Parts 333 and 369 (Docket # 75N-183H), Federal Register Volume 59, Number 116, Friday, June 17, 1994, Proposed Rules. However, the product need not be controlled like a pharmaceutical drug. The product may be stored and controlled similarly to an iodine or alcohol skin preparation product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal povidone-iodine</intervention_name>
    <description>povidone-iodine USP, 10% w/w antiseptic</description>
    <arm_group_label>Nasal povidone-iodine</arm_group_label>
    <other_name>PROFEND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing operative fixation of lower extremity fractures at the University&#xD;
             of Iowa during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to provide informed consent due to head trauma or dementia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marin L Schweizer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Marin L. Schweizer, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>nasal decolonization</keyword>
  <keyword>Orthopedic trauma surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

